NCT00170846View on ClinicalTrials.gov

ASCERTAIN: Assessment of Everolimus in Addition to Calcineurin Inhibitor Reduction in the Maintenance of Renal Transplant Recipients

PHASE4CompletedINTERVENTIONAL
Enrollment

394

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Renal Transplantation
Interventions
DRUG

Everolimus (RAD001)

DRUG

Calcineurin Inhibitors (CNI)

DRUG

Mycophenolate acid (MPA)/Azathioprine (AZA)

DRUG

Steroids

Trial Locations (1)

Unknown

Novartis, Basel

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY